Francois Godart1, Alban-Elouen Baruteau2, Jérôme Petit2, Jean-Yves Riou2, Francois Sassolas3, Jean R Lusson4, Alain Fraisse5, Younes Boudjemline6. 1. EA 2693, service de cardiologie infantile et congénitale, université Lille 2 Nord de France, hôpital cardiologique, CHRU de Lille, 59037 Lille cedex, France. Electronic address: francois.godart@chru-lille.fr. 2. Centre chirurgical Marie-Lannelongue, Le Plessis-Robinson, France. 3. Cardiologie pédiatrique, hôpital Louis-Pradel, Lyon, France. 4. Service de cardiologie et maladies cardiovasculaires, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France. 5. Cardiologie pédiatrique, hôpital de la Timone-Enfants, Marseille, France. 6. Cardiologie infantile, université Paris Descartes, hôpital Necker Enfants-Malades, Paris, France.
Abstract
BACKGROUND: Transcatheter valve-in-valve (VIV) implantation in failing bioprosthesis is an emerging field in cardiology. AIM: To report on a French multicentre experience and a literature review of tricuspid VIV implantation. METHODS: We approached different institutions and collected 10 unpublished cases; a literature review identified 71 patients, including our 10 cases. Clinical aspects and haemodynamic data are discussed. RESULTS: Among our 10 unpublished cases, the reason for implantation was significant tricuspid stenosis (n = 4), significant tricuspid regurgitation (n = 1) or mixed lesion (n = 5). Implantation was performed under general anaesthesia at mean age 28 ± 17 years. The 22 mm Melody valve was implanted in seven patients; the Edwards SAPIEN valve was implanted in three patients. The procedure succeeded in all cases, despite two embolizations in the right cardiac chambers; in both cases, the valve was stabilized close to the tricuspid annulus using a self-expandable stent, before implantation of a second Edwards SAPIEN valve. Functional class improved in all but one case. Mean diastolic gradient decreased from 9 ± 2.45 mmHg to 3.65 ± 0.7 mmHg (p = 0.007); no more than trivial regurgitation was noticed. Among the published cases, the Melody valve was implanted in 41 patients, the Edwards SAPIEN valve in 29 patients and the Braile valve in one patient. Short-term results were similar for our 10 cases, but mid-term results are not yet available. CONCLUSIONS: Tricuspid VIV implantation using the Melody or Edwards SAPIEN valves is a feasible and effective procedure for selected patients with failing bioprosthesis.
BACKGROUND: Transcatheter valve-in-valve (VIV) implantation in failing bioprosthesis is an emerging field in cardiology. AIM: To report on a French multicentre experience and a literature review of tricuspid VIV implantation. METHODS: We approached different institutions and collected 10 unpublished cases; a literature review identified 71 patients, including our 10 cases. Clinical aspects and haemodynamic data are discussed. RESULTS: Among our 10 unpublished cases, the reason for implantation was significant tricuspid stenosis (n = 4), significant tricuspid regurgitation (n = 1) or mixed lesion (n = 5). Implantation was performed under general anaesthesia at mean age 28 ± 17 years. The 22 mm Melody valve was implanted in seven patients; the Edwards SAPIEN valve was implanted in three patients. The procedure succeeded in all cases, despite two embolizations in the right cardiac chambers; in both cases, the valve was stabilized close to the tricuspid annulus using a self-expandable stent, before implantation of a second Edwards SAPIEN valve. Functional class improved in all but one case. Mean diastolic gradient decreased from 9 ± 2.45 mmHg to 3.65 ± 0.7 mmHg (p = 0.007); no more than trivial regurgitation was noticed. Among the published cases, the Melody valve was implanted in 41 patients, the Edwards SAPIEN valve in 29 patients and the Braile valve in one patient. Short-term results were similar for our 10 cases, but mid-term results are not yet available. CONCLUSIONS: Tricuspid VIV implantation using the Melody or Edwards SAPIEN valves is a feasible and effective procedure for selected patients with failing bioprosthesis.
Authors: Jayendrakumar S Patel; Samir R Kapadia; Lourdes Prieto; E Murat Tuzcu; Amar Krishnaswamy Journal: Curr Treat Options Cardiovasc Med Date: 2015-11
Authors: Marcin Demkow; Witold Rużyłło; Sebastian Bujak; Marek Konka; Piotr Szatkowski; Barbara Lubiszewska Journal: Postepy Kardiol Interwencyjnej Date: 2016-02-11 Impact factor: 1.426
Authors: Brunno Lemes de Melo; Stella S Vieira; Ednei L Antônio; Luís F N Dos Santos; Leslie A Portes; Regiane S Feliciano; Helenita A de Oliveira; José A Silva; Paulo de Tarso C de Carvalho; Paulo J F Tucci; Andrey J Serra Journal: Front Physiol Date: 2016-12-05 Impact factor: 4.566
Authors: Philipp Lake; Elmar W Kuhn; Victor Mauri; Sascha Macherey; Julia Kaliba; Stephan Baldus; Christian Frerker; Tobias Schmidt Journal: Clin Res Cardiol Date: 2021-04-28 Impact factor: 5.460